No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 13.660
- +0.340+2.55%
Close Apr 30 16:00 ET
- 17.290
- +3.630+26.57%
Pre 08:37 ET
2.11BMarket Cap151.78P/E (TTM)
13.750High12.930Low5.21MVolume13.300Open13.320Pre Close70.46MTurnover3.60%Turnover Ratio151.78P/E (Static)154.54MShares35.22052wk High13.15P/B1.98BFloat Cap6.46052wk Low--Dividend TTM144.65MShs Float149414.006Historical High--Div YieldTTM6.16%Amplitude0.956Historical Low13.532Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Predictive POAI Flugen Collaboration; TG Therapeutics TGTX Earnings
TG Therapeutics Updates 2024 Briumvi U.S. Net Product Revenue Target To Approximately $270M-$290M Versus Prior Guidance Of $220M-$260M
TG Therapeutics Updates 2024 Briumvi U.S. Net Product Revenue Target To Approximately $270M-$290M Versus Prior Guidance Of $220M-$260M
TG Therapeutics Targets Q2 2024 Briumvi U.S. Net Product Revenue Of Approximately $65M
TG Therapeutics Targets Q2 2024 Briumvi U.S. Net Product Revenue Of Approximately $65M
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, Vs. Street Est of $54.6M
07:04 AM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M
TG Therapeutics 1Q Loss/Shr 7c >TGTX
TG Therapeutics 1Q Loss/Shr 7c >TGTX
Press Release: TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg